SPRYCEL® (dasatinib) Demonstrates Superior Confirmed Complete Cytogenetic Response Rates Compared to Gleevec®* in Study of Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

On June 5, 2010

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219

Related Post

Modification to the Methodology of the S&P ESG Leaders Indices

Modification to the Methodology of the S&P Carbon Control Index Series

MACOM Technology Solutions Holdings Set to Join S&P MidCap 400